SecBot SecBot

RGEN

REPLIGEN CORP
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0000730272 Biotech & Drug Discovery
$162.78 −5.01 (−2.99%)
Nov 16 4:00 PM ET · prev $167.79
Market cap
$10.6B
Large cap
Consensus
Buy
81% Buy or better · 27 analysts
Median target
$200.00
+23% · range $175.00–235.00
1 year
+9.2%
from $149.00 · Nov 17
30 days
−7.7%
from $176.43
52-week range
$102.87–194.57
−16% from high · low May 15
Avg volume 20D
1.25M
Oct 30 spike 4.47M
Short interest
7.05M
≈11.0% of shares · −1.3%
Days to cover
4.9
at average volume
Insider net
−$6.7M
0 buyers · 2 sellers · since Mar 4
New fund stakes
4
Q2 2026 13F · 1 exit
Filing reports
14
analyzed by SecBot
SecBot read BULLISH 9 reports · 90 days
Balance 0 bearish · 5 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 7/9

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $6.7M.

  • InstitutionsBULLISH

    Q2 2026: 37 added (4 new), 23 trimmed or exited. Largest new: William Blair Investment Management $107.6M, Marshall Wace $38.5M.

  • AnalystsBULLISH

    22 of 27 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.581 → $0.524 over 90 days. 0 up, 12 down in 30 days.

  • Short sellersSTEADY

    Short interest −1.3% to 7.05M shares. 4.9 days to cover, ≈11.0% of shares.

  • TrendDOWNTREND

    8% below its 50-day average.

Who's buying

13F· Q2 2026
4
new positions
1
exit
$168.0M
in new stakes
FundMoveSharesValue
MAVERICK CAPITAL LTDADD1,984,554$270.8M
PRICE T ROWE ASSOCIATES INC /MD/TRIM1,752,274$239.1M
WASATCH ADVISORS LPADD1,590,251$217.0M
AMERIPRISE FINANCIAL INCADD1,576,132$215.0M
Holocene Advisors, LPADD1,292,191$176.3M
CONGRESS ASSET MANAGEMENT COADD1,012,226$138.1M
GOLDMAN SACHS GROUP INCADD965,411$131.7M
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLCNEW788,571$107.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

27 analysts
Buy 81% rate it Buy or better
Strong Buy7Buy15Hold5Sell0Strong Sell0
12-month targets · 19 analysts

Price is below the lowest target. Median implies +23%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Oct 28, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Oct 19, 2026Canaccord Genuity
MAINTAIN
MAINTAINHold
Oct 7, 2026Barclays
MAINTAIN
MAINTAINOverweight
Sep 9, 2026UBS
MAINTAIN
MAINTAINBuy
Jul 30, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Jul 29, 2026JP Morgan
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$6.7M
sold · 2 insiders
DateInsiderTypeValue
Oct 6, 2026
Douglass Brian Robb
CHIEF PRODUCT OFFICER
Oct 6, 2026
AWARD675 sh
Oct 6, 2026
Douglass Brian Robb
CHIEF PRODUCT OFFICER
Oct 6, 2026
AWARD700 sh
Oct 5, 2026
Loeillot Olivier
Chief Executive Officer
Oct 5, 2026
EXERCISE$651.1K
Oct 5, 2026
Loeillot Olivier
Chief Executive Officer
Oct 5, 2026
SELL$238.3K
Oct 5, 2026
Loeillot Olivier
Chief Executive Officer
Oct 5, 2026
SELL$798.4K
Oct 2, 2026
Loeillot Olivier
Chief Executive Officer
Oct 2, 2026
TAX W/H$226.8K
Sep 25, 2026
Garland Jason K
CFO
Sep 25, 2026
TAX W/H$79.9K
Sep 24, 2026
Loeillot Olivier
Chief Executive Officer
Sep 24, 2026
EXERCISE$705.7K

Earnings setup

Estimates
$0.52
EPS estimate, this quarter
−10%
estimate change, 90 days
0↑ 12↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.52$0.50–$0.55-9.9%$241.1M
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
7,054,160
shares short
-1.3%
vs prior settlement
4.9
days to cover
≈11.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 6, 2026 SEC
Repligen issued $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031. Approximately…
8-K · Impact 4/10
Nov 4, 2026 Other
Repligen Corporation to Present at Jefferies Global Healthcare Conference
WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announce
Oct 30, 2026 SEC
Repligen entered into privately negotiated exchange and subscription agreements to issue $1.0 billion aggregate…
8-K · Impact 5/10
Oct 27, 2026 SEC
Repligen reported Q3 2026 revenue of $209.3M, up 11% YoY as reported and 12.5% organic, beating the $206.7M consensus…
8-K · Impact 6/10
Oct 6, 2026 Press
Repligen completed its acquisition of BioLife Solutions, paying $11.25 per share in cash plus 0.1442 shares of…
Impact 6/10
Oct 6, 2026 Insider
Douglass Brian Robb was granted 675 shares
CHIEF PRODUCT OFFICER
Oct 6, 2026 Insider
Douglass Brian Robb was granted 700 shares
CHIEF PRODUCT OFFICER
Oct 5, 2026 Insider
Loeillot Olivier acquired via exercise 4,202 shares
Chief Executive Officer @ $154.96 ($651.1K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 4, 2026
Press release
Repligen Corporation to Present at Jefferies Global Healthcare Conference
WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that it will participate in the Jefferies…
Oct 30, 2026
Press release
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (“Repligen”), today announced that it entered into privately…
Oct 27, 2026
Earnings
Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
WALTHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today reported financial results for its third quarter of…
Oct 27, 2026
Earnings result
RGEN Q3 2026 Earnings: EPS $0.53 (+12.8% vs est)
Oct 6, 2026
M&A
Repligen Completes Acquisition of BioLife Solutions
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused…

SecBot reports

14 filings · 2 press releases · 8 bullish · 0 bearish · 1 mixed · 5 neutral
All RGEN filing & press-release reports (16)